SCD Stock Overview
Engages in the production and marketing of preparations and medicines for human use in Romania and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for SCD from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Zentiva S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | RON 4.52 |
| 52 Week High | RON 4.60 |
| 52 Week Low | RON 2.78 |
| Beta | 0.36 |
| 1 Month Change | 0% |
| 3 Month Change | 12.44% |
| 1 Year Change | 61.43% |
| 3 Year Change | 83.74% |
| 5 Year Change | 40.37% |
| Change since IPO | 9,000.06% |
Recent News & Updates
Recent updates
Take Care Before Diving Into The Deep End On Zentiva S.A. (BVB:SCD)
Jul 30
Zentiva S.A. (BVB:SCD) Doing What It Can To Lift Shares
Mar 02Zentiva's (BVB:SCD) Solid Earnings May Rest On Weak Foundations
May 24Zentiva (BVB:SCD) Has Gifted Shareholders With A Fantastic 201% Total Return On Their Investment
Mar 01Zentiva S.A.'s (BVB:SCD) Stock Is Going Strong: Have Financials A Role To Play?
Jan 25
Zentiva S.A. (BVB:SCD) Investors Are Less Pessimistic Than Expected
Dec 18Shareholder Returns
| SCD | RO Pharmaceuticals | RO Market | |
|---|---|---|---|
| 7D | 0% | -7.3% | -3.4% |
| 1Y | 61.4% | -3.3% | 5.2% |
Return vs Industry: SCD exceeded the RO Pharmaceuticals industry which returned -3.3% over the past year.
Return vs Market: SCD exceeded the RO Market which returned 5.2% over the past year.
Price Volatility
| SCD volatility | |
|---|---|
| SCD Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in RO Market | 12.0% |
| 10% least volatile stocks in RO Market | 2.9% |
Stable Share Price: SCD has not had significant price volatility in the past 3 months compared to the RO market.
Volatility Over Time: SCD's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1962 | 1,035 | Simona Cocos | www.zentiva.ro |
Zentiva S.A. engages in the production and marketing of preparations and medicines for human use in Romania and internationally. The company develops pharmaceutical products in various therapeutic areas, such as cardiovascular diseases, anti-inflammatory and pain-relieving medications, urologists, blood diseases, gastrointestinal and metabolic disorders, central nervous system, infections, respiratory systems, and other. It also offers educational materials for healthcare professionals and patients.
Zentiva S.A. Fundamentals Summary
| SCD fundamental statistics | |
|---|---|
| Market cap | RON 3.15b |
| Earnings (TTM) | RON 270.78m |
| Revenue (TTM) | RON 1.09b |
11.6x
P/E Ratio2.9x
P/S RatioIs SCD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCD income statement (TTM) | |
|---|---|
| Revenue | RON 1.09b |
| Cost of Revenue | RON 470.10m |
| Gross Profit | RON 623.98m |
| Other Expenses | RON 353.20m |
| Earnings | RON 270.78m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.39 |
| Gross Margin | 57.03% |
| Net Profit Margin | 24.75% |
| Debt/Equity Ratio | 0% |
How did SCD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 00:15 |
| End of Day Share Price | 2024/11/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zentiva S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|